Results 101 to 110 of about 9,302 (232)

Real-world adverse event profiles of Zuranolone and Brexanolone based on FAERS and VigiAccess databases: An observational study

Zuranolone and Brexanolone are Food and Drug Administration-approved novel agents for postpartum depression, yet real-world post-marketing safety data for the two drugs remain insufficient.
Liqun Chi, Guanbo Xie, Jingxian Yu, Huili Weng   +3 more
core   +1 more source

Broadening the capture of natural products mentioned in FAERS using fuzzy string-matching and a Siamese neural network

Scientific Reports
Increased sales of natural products (NPs) in the US and growing safety concerns highlight the need for NP pharmacovigilance. A challenge for NP pharmacovigilance is ambiguity when referring to NPs in spontaneous reporting systems.
Israel O. Dilán-Pantojas, Tanupat Boonchalermvichien, Sanya B. Taneja, Xiaotong Li, Maryann R. Chapin, Sandra Karcher, Richard D. Boyce   +6 more
doaj   +1 more source

Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System (FAERS) Database

Drug, Healthcare and Patient Safety, 2023
Teresa A Simon,1 John H Simon,1 Erin G Heaning,1 Andres Gomez-Caminero,1 Jahan P Marcu1,2 1Physicians Research Center, LLC, Toms River, NJ, USA; 2Marcu Enterprises, Jersey City, NJ, USACorrespondence: Teresa A Simon, Physicians Research Center, LLC, Toms
Simon TA, Simon JH, Heaning EG, Gomez-Caminero A, Marcu JP   +4 more
doaj  

Disproportionality analysis of interstitial lung disease associated with novel antineoplastic agents during breast cancer treatment: a pharmacovigilance studyResearch in context

EClinicalMedicine
Summary: Background: Studies have shown that some antineoplastic agents may be associated with interstitial lung disease (ILD), but large-scale real-world data are lacking.
Zijun Zhu, Yongxin Li, Chaoyong Zhu, Qiuxia Dong, Yixiao Zhang, Zhilin Liu, Dengfeng Ren, Fuxing Zhao, Jiuda Zhao   +8 more
doaj   +1 more source

Reported safety events from ultrasound enhancing agents: a critical reappraisal

Echo Research and Practice
Background Reported adverse events (AEs) to the Food and Drug Administration Adverse Event Reporting System (FAERS) have suggested an increased rate of serious AEs (SAEs) during the COVID-19 pandemic, but the extent to which this may be related to ...
Jordan B. Strom, Nicholas Spetko, Constance E. M. Angell-James, Madeline A. Cassidy, Jessica L. Stout, Morgan L. Winburn, Rebecca Lee, Alecia Bradley, Kevin Moreau, Venkateshwar Polsani, Cosby A. Stone   +10 more
doaj   +1 more source

Drug-induced dementia: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database

Therapeutic Advances in Neurological Disorders
Background: Dementia is a serious adverse event (AE) that requires attention in clinical practice. However, information on drug-induced dementia is limited. The U.S.
Lisi Xu, Ruonan Zhang, Xiaolin Zhang, Xiuli Shang, Daifa Huang   +4 more
doaj   +1 more source

Safety evaluation of irinotecan: a real-world disproportionality analysis using FAERS and JADER databases during the time period 2004-2024

Frontiers in Pharmacology
IntroductionIrinotecan is a widely used chemotherapeutic agent for treating colorectal, pancreatic, and ovarian cancers. Despite its therapeutic efficacy, the safety profile of irinotecan necessitates continuous pharmacovigilance due to its association ...
Siyu Lou, Huayou Chen, Zhiwei Cui, Xiyuan Zhang, Chengyu Zhu, Linmei Zhou, Yingyong Ou, Fan Zou   +7 more
doaj   +1 more source

Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)

The safety information of brolucizumab primarily comes from clinical trials experience. This study aimed to explore the ocular and systemic adverse events (AEs) associated with brolucizumab among real-world patients through data mining the FDA Adverse ...
Taomin Huang (3796603), Xiaomei Xiong (14854087), Xiuwen Zhang (1534498), Xiaoxia Li (209011)   +3 more
core   +1 more source

FAER and Others [PDF]

Anesthesiology, 2011
openaire   +1 more source

Post-marketing safety signals of Wilson’s disease therapies: evidence from FAERS and VigiBase

Orphanet Journal of Rare Diseases
Introduction Wilson’s disease is a rare autosomal copper metabolism recessive disorder that requires lifelong pharmacological treatment. D-penicillamine and trientine are the most commonly used copper chelators.
Hülya Tezel-Yalçın, Nadir Yalçın, Karel Allegaert, Pınar Erkekoğlu   +3 more
doaj   +1 more source